These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16681695)

  • 1. TTF-1 expression in primary ovarian epithelial neoplasia.
    Graham AD; Williams AR; Salter DM
    Histopathology; 2006 May; 48(6):764-5. PubMed ID: 16681695
    [No Abstract]   [Full Text] [Related]  

  • 2. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
    Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
    APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma.
    Lin CK; Chao TK; Lai HC; Lee HS
    Am J Clin Pathol; 2012 Jun; 137(6):971-7. PubMed ID: 22586057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
    Hu YQ; Liu YJ
    Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological classification of ovarian cancer.
    Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
    Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
    Zhang MZ; Qiao YH; Suo ZH
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma].
    Shi HR; Song WJ; Chen ZM; Wu QH
    Ai Zheng; 2005 Sep; 24(9):1127-31. PubMed ID: 16159439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
    Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
    Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WT-1 in ovarian and endometrioid serous carcinoma: a meta-analysis.
    Heatley MK
    Histopathology; 2005 Apr; 46(4):468. PubMed ID: 15810962
    [No Abstract]   [Full Text] [Related]  

  • 14. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma.
    Takai N; Miyazaki T; Nishida M; Nasu K; Miyakawa I
    Int J Mol Med; 2002 Aug; 10(2):211-6. PubMed ID: 12119561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas.
    Sarrió D; Moreno-Bueno G; Sánchez-Estévez C; Bañón-Rodríguez I; Hernández-Cortés G; Hardisson D; Palacios J
    Hum Pathol; 2006 Aug; 37(8):1042-9. PubMed ID: 16867867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
    Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
    Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.
    Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL
    Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and clinical significance of TLR9 in ovarian cancer].
    Sha HL; Ouyang WX; Lü G
    Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):913-6. PubMed ID: 21223799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
    Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
    Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.